TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04962087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Health enSuite Insomnia
Description: Health enSuite: Insomnia has been designed based on established cognitive behavioural treatments for insomnia and adapted to fit an automated interactive platform available via an internet enabled device. The program is divided into a series of treatment modules or levels that will be delivered over the course of 6-8 weeks. The content of these 6 levels includes the following components, a sleep diary, sleep restriction clock, sleep hygiene, relaxation techniques, sleep related thoughts and beliefs, and involving a support person.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Health enSuite Insomnia - Deprescribing
Description: All participants in Trial 2 will be initiating a gradual medication tapering schedule recommended to them by their physician. The module physicians use to refer their patients to the study includes a section where they fill out a brief drug history for sleep medications. This information is then used to generate a tapering schedule that the health care provider will review with their patient. Health care providers are responsible for providing appropriate medication counselling and follow-up care to supervise deprescribing. This study does not place any restriction on the usual care participants will receive.
Study: NCT06044246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF membrane
Description: Placing implant with PRF membrane treatment
Study: NCT04446611

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First antenatal care + test-of-cure
Description: Single point-in-time molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and infection-specific test-of-cure 3 weeks post-treatment. Women with a positive test-of-cure will be re-treated. As CT/NG is a combined Xpert test, women who present with an incident infection (newly diagnosed infection) will be treated and managed accordingly.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: First antenatal care + week 30-34 gestation (no test-of-cure)
Description: Repeated molecular point-of-care diagnostic screening and treatment for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis at first antenatal care visit and at week 30-34 gestation. No test-of-cure will be conducted for women with positive test results; however, additional treatment will be provided to women with persistent/recurrent vaginal discharge.
Study: NCT06050642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced care model provided by Timkl, a home support provider
Description: A new type of care provided by timkl, a home support provider, involving nurses and the dispensing pharmacist. This approach combines the current tasks of the service provider's nurses with closer monitoring by the pharmacist, thanks to more frequent contacts and a holistic view of the patient.
Study: NCT05989919

Intervention type: OTHER
Intervention: CT scan for nose and paranasal sinuses
Description: CT scan for nose and paranasal sinuses

Intervention type: OTHER
Intervention: CT scan for nose and paranasal sinuses
Description: CT scan for nose and paranasal sinuses
Study: NCT05977868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid
Description: COpAT (oral antimicrobial therapy) on hospital discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Description: Standard of care (IV antimicrobial therapy) on hospital discharge
Study: NCT05792137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat challenge meal
Description: High saturated fat challenge meal made with palm oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat challenge meal
Description: High saturated fat challenge meal made with palm oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High mono unsaturated fat challenge meal
Description: High mono unsaturated fat challenge meal made with olive oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High mono unsaturated fat challenge meal
Description: High mono unsaturated fat challenge meal made with olive oil
Study: NCT06039605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation (tDCS) is a minimal risk, non-invasive, neuromodulatory technique that involves the emission of a weak electrical current, traditionally via the placement of two electrodes attached to the scalp of a participant. tDCS is widely used for research purposes, the US FDA considers trials of tDCS as non-significant-risk. There are several review articles supporting the safety of tDCS usage in controlled human trials. According to a published meta-analysis , the use of conventional tDCS protocols in human trials (≤40 min, ≤4 mA) has not produced any reports of a Serious Adverse Effect or irreversible injury across over 33,200 sessions.
Study: NCT04844983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
Study: NCT04020055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl 150 mg
Description: migalastat HCl 150 mg capsule
Study: NCT04844983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Saline
Description: Normal Saline

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Saline
Description: Normal Saline
Study: NCT05242536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse- led program
Description: A nurse coordinated multidisciplinary program aiming to improve psychosocial problems has been developed and will be applied to the patients in the experimental group. This nurse-led program will start at discharge and continue for three months.
Study: NCT05337995

Intervention type: OTHER
Intervention: Quantified analysis of walking during a task of passage through a horizontal opening
Description: Functional test that reproduce a task of daily living, similar to a doorway

Intervention type: OTHER
Intervention: Quantified analysis of walking during a task of passage through a horizontal opening
Description: Functional test that reproduce a task of daily living, similar to a doorway
Study: NCT06218342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: Besides lifestyle intervention and background medication, participants will be prescribed Henagliflozin at standard clinical doses.

Intervention type: OTHER
Group type: OTHER
Intervention: Background medication
Description: Participants will only receive lifestyle intervention and background medication.
Study: NCT04923932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Patients meeting the study inclusion criteria will receive Savolitinib \[Savolitinib 600 mg, po, once per day (QD) continuously in patients with baseline weight ≥50 kg, and Savolitinib 400 mg, po, QD in patients with baseline weight \<50 kg\] in 21 day treatment cycle, until disease progression, death, intolerable toxicity or other termination criteria as specified in the protocol, whichever occurs earliest.
Study: NCT05403034

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsy
Description: Peroperative muscle biopsy will be performed during a planned shoulder surgery (arthrolysis and/or muscle transfer)
Study: NCT05384249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study: NCT05695118

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-contrast low-dose abdomen CT
Description: target effective dose: \< 1.5 mSv It is performed twice in 6-month interval.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: Fibroscan is performed within a week of low-dose CT. It is used as a reference standard of hepatic fibrosis and steatosis.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bioelectrical impedance analysis (BIA)
Description: BIA test is performed on the same day of low-dose CT. Commercially available model (Inbody 270) is used.
Study: NCT05249387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-967079 and BAM8-22 application
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-967079 and BAM8-22 application after 5 minutes.
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-967079 application.
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle and BAM8-22 application.
Description: Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT04684667

Intervention type: DRUG
Group type: OTHER
Intervention: Propranolol Therapy for Infantile Hemangioma
Description: If there are no contraindications to propranolol, it will be given at initial dose of 0.5 mg /kg/day in 2-3 divided doses with feeds and the patients will be observed for clinical signs of serious adverse reactions. If the dose is tolerated, it will be maintained for four to seven days, and then it will be increased by 0.5mg/kg/day every four days to the target dose of 2mg/kg/day. The patients will be observed for 2 hours after each dose increase for the clinical signs of severe side effects.
Study: NCT06786338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-9768
Description: SGB-9768 for subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-9768
Description: SGB-9768 for subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGB-9768
Description: SGB-9768 for subcutaneous (SC) injection
Study: NCT06787638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: full dose of Neostigmine
Description: • Group A: received 10ml (a full dose of Neostigmine (0.08 mg/kg) plus Atropine (20 mic/kg+7ml normal saline)~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: half dose of Neostigmine
Description: • Group B: received 10ml (a half dose of Neostigmine (0.04 mg/kg) plus Atropine (20 mic/kg+8ml normal saline).~Measured using ultrasound Time frame: preoperatively and at zero, 10 minutes and 30 minutes postoperatively.
Study: NCT06785376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIY (Do It Yourself)
Description: DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIY (Do It Yourself)
Description: DIY is 3-session program that promotes empowerment, autonomy, stigma coping/resistance and social support to promote sexual health and pleasure and HIV prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRUST
Description: TRUST is a single-session HIV self-testing training with facilitator

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRUST
Description: TRUST is a single-session HIV self-testing training with facilitator

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: standard of care single-session, low threshold peer/near-peer navigation to PrEP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC
Description: standard of care single-session, low threshold peer/near-peer navigation to PrEP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC
Description: standard of care single-session, low threshold peer/near-peer navigation to PrEP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC
Description: standard of care single-session, low threshold peer/near-peer navigation to PrEP.
Study: NCT06787131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 100 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 100 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg)
Description: Itraconazole 200 mg twice per day on Day-4 and once per day on Days-3 to 8, inclusive

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 200 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 200 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 200 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 400 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 400 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 800 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 800 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 1600 mg ZE50-0134 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZE50-0134 or placebo
Description: 1600 mg ZE50-0134 or placebo
Study: NCT06783582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing based on Pender's health promotion model
Description: In addition to routine nursing care, patients will be given a motivational interview intervention based on Pender's health promotion model. This intervention will be carried out in a total of 6 sessions, three face-to-face sessions and three online sessions planned individually for each patient. The interviews will last approximately 30-45 minutes. The first motivational interview will be held on the 1st day of the patient's admission to the clinic, the second motivational interview on the 4th day, and the third motivational interview on the 7th day. The face-to-face sessions will be conducted by the researcher in the hospital's education room and contact information will be obtained from the patients. The following three interviews will be held online with the patients once a week via the WhatsApp application. The patient will be contacted at least two days before the interviews, an appointment will be made, and the interview day and time will be determined.
Study: NCT06785220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORAL FACIAL FACILITATION
Description: A group will receive oral facial facilitation which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORAL MOTOR THERAPY
Description: B group will receive oral motor therapy which included exercise for given,~1. A volcano bubbles~2. Party blower target~3. Bubble blowing~4. Curly straws

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ORAL FACIAL FACILITATION WITH ORAL MOROR THERAY
Description: C group will receive oral facial facilitation and oral motor therapy which included exercise for given,~1. Brushing~2. Vibration~3. Manipulation (stroking and tapping)~4. Oral motor sensory exercise (lip, tongue, swallowing exercises)~5. A volcano bubbles~6. Party blower target~7. Bubble blowing~8. Curly straws
Study: NCT06007924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib 200 mg twice daily 3 weeks on/1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib 200 mg twice daily 3 weeks on/1 week off
Study: NCT06783179

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06784206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy
Description: Chemotherapy:~Etoposide will be administered intravenously at a dose of 100 mg/m² on days 1 to 3 of each cycle. Cisplatin will be given at a dose of 75 mg/m² on day 1 of each cycle. The treatment will be repeated every 3 weeks for a total of 4 cycles.~Concurrent Radiotherapy:~Chest radiotherapy will be initiated concurrently with the first 3 cycles of chemotherapy. The total dose of radiotherapy will be 54 Gy, delivered in 30 fractions, with 2 fractions per day.~Prophylactic Cranial Irradiation (PCI):~For patients who achieve a partial response (PR) or complete response (CR) after chemoradiotherapy, PCI will be administered 3 to 4 weeks after the completion of chemoradiotherapy. The dose for PCI will be 25 Gy in 10 fractions.~Adebrelimab Maintenance Therapy:~Following PCI, patients will receive maintenance therapy with Adebrelimab. The dose will be 1200 mg administered intravenously on day 1 of each cycle. The treatment will be repeated every 3 weeks until disease progression, death
Study: NCT06784375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unblinded CGM/Nutrition Therapy
Description: Personalized nutrition counseling based on CGM data

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blinded CGM/Nutrition Therapy
Description: Standard nutrition education which does not incorporate CGM data

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unblinded CGM/No Nutrition Therapy
Description: CGM and general diabetes education (no nutrition education)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blinded CGM/No Nutrition Therapy
Description: General diabetes education (no nutrition education)